‘Exciting time’: Biologic use in moderate to severe lupus rose 45% since 2021
Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent findings from a market analysis conducted by Spherix Global Insights.The analysis additionally found that nearly half of moderate-to-severe patients with SLE are currently on a biologic. Meanwhile, among those not currently on a biologic, 73% are considered a